MELISSA BROWN: Open Payments
NPI 1669900346 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$440 in 25 payments from 9 companies in 2025. Trend: 2023 $301 · 2024 $420 · 2025 $440
Food & beverage: $440
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $182 |
| Janssen Pharmaceuticals, Inc | 2 | $48 |
| PFIZER INC. | 2 | $42 |
| Abbott Laboratories | 2 | $39 |
| Gilead Sciences, Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $33 |
| Lundbeck LLC | 1 | $21 |
| Novo Nordisk Inc | 1 | $20 |
| Amgen Inc. | 1 | $16 |
Products named: VRAYLAR, SPRAVATO, FREESTYLE LIBRE 3, MOUNJARO, UBRELVY, PAXLOVID, REXULTI, PREVNAR 20.
Industry payments across KY — which companies pay providers there.
